Distinct Nuclear DNA Structure in Immune Cells From Centenarians

Key Takeaways

• Centenarians show globally open chromatin in immune cells.
• B cells retain promoter accessibility normally lost with age.
• ERG transcription factor forms phase-separated condensates reducing senescence.
• ERG condensation downregulates CDKN2A expression.
• Epigenetic resilience may underpin exceptional longevity.

Summary

Researchers identified a unique chromatin accessibility signature in peripheral blood mononuclear cells of centenarians, marked by widespread chromatin openness across multiple immune subsets. Unlike typical aging, which often links increased accessibility with senescence, centenarians maintain open promoters and enhancers in B cells that usually close with age. The ETS‑related transcription factor ERG emerged as a key longevity‑associated regulator, forming nuclear condensates via liquid‑liquid phase separation. ERG condensates suppress senescence‑related genes such as CDKN2A, suggesting a mechanistic link between epigenetic architecture and extreme longevity.

Pulse Analysis

The study of centenarian immune cells uncovers a paradoxical epigenetic landscape where chromatin remains unusually accessible, defying the conventional view that aging drives widespread heterochromatin loss and functional decline. By profiling peripheral blood mononuclear cells, scientists observed that B‑cell promoters and enhancers, typically silenced in older adults, stay open, supporting continued transcription of genes vital for immune surveillance. This global openness appears to preserve genomic stability, positioning chromatin architecture as a cornerstone of exceptional longevity.

At the heart of this epigenetic signature lies the transcription factor ERG, an ETS‑family protein that undergoes liquid‑liquid phase separation to create nuclear condensates. These condensates reorganize chromatin topology, directly repressing senescence‑associated loci such as CDKN2A. Functional assays demonstrate that ERG‑driven phase separation attenuates classic senescence phenotypes, linking biophysical properties of transcription factors to tangible anti‑aging outcomes. The mechanistic insight bridges epigenomics with protein chemistry, highlighting a novel regulatory layer that can be harnessed for therapeutic gain.

The broader implications extend to drug discovery and precision medicine. Targeting ERG’s phase‑separation capacity—or mimicking its chromatin‑opening effects—could rejuvenate aged immune systems, reducing infection susceptibility and inflammatory disorders common in the elderly. Moreover, the centenarian chromatin blueprint offers a template for designing epigenetic interventions that bolster immune resilience without compromising genomic integrity. As the biotech industry seeks actionable longevity pathways, ERG and its condensate dynamics emerge as promising candidates for next‑generation anti‑aging therapeutics.